Gland Pharma Reports 47% Profit Growth and Signs Five-Year Global CDMO Pact
Gland Pharma reported a 47% year-on-year rise in net profit to approximately Rs 317 crore for the June 2026 quarter, with sales increasing nearly 20% to Rs 1,800 crore. The growth was driven by its Contract Development and Manufacturing Organization (CDMO) and B2B businesses, particularly in the US and Europe. The company also announced a five-year strategic manufacturing and supply agreement with a global pharmaceutical firm, expected to generate significant revenue from 2029 onwards and expand its product portfolio across multiple injectable formats.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 35/100.
Outlets measured: businessstandard, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 9 Aug, 05:50 am. Other outlets followed.